A Diversified Portfolio of Generic and Specialty Pharmaceutical Products

On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

About Amneal + Impax Products

In the US, our combined Amneal + Impax generics portfolio of approximately 200 generic product families* provides patients with more affordable access to quality medicines.

Our growing Specialty Pharma business, operating as Impax, delivers products that meet important medical needs in central nervous system disorders, parasitic infections and other therapeutic categories.

We are also excited about our work to bring patients more affordable biologic therapy options through our biosimilars program, which today includes one filed product and one near-term filing opportunity.

 

*As of April 16, 2018